Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
Today we announced that in response to its October 2022 Pre-Request for Designation (Pre-RFD) for our investigational Celularity Tendon Wrap (CTW), the U.S. Food and Drug Administration (FDA) has reviewed information provided by the Company and other relevant available information, and agreed with the Company’s recommendation that its investigational CTW product be regulated as a device by the FDA Center for Devices and Radiologic Health (CDRH).
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Letter to shareholders
Celularity Inc. Announces $3 Million Registered Direct Offering
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies
Celularity Announces Presentation At Upcoming 7th International Conference On Orthopedics
Celularity Tissue Factor Gene Knockout Of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance Of Gene Editing Capability
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients With Relapsed Refractory And Measurable Residual Disease-positive Acute Myeloid Leukemia
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”
Celularity Inc. Announces $6 Million Registered Direct Offering
Celularity Announces Acceptance of Poster Presentation at 2023 Society For Biomaterials Annual Meeting
Celularity Receives U.S. Food and Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders For Celularity Branded Halal-Certified Biomaterial Products
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW) To Be Regulated As A Device Within U.S. Food and Drug Administration (FDA) Center For Devices and Radiological Health (CDRH)